Opendata, web and dolomites

CLINGLIO SIGNED

A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CLINGLIO project word cloud

Explore the words cloud of the CLINGLIO project. It provides you a very rough idea of what is the project "CLINGLIO" about.

cancer    ratio    tumor    rates    therapies    drug    treatments    repressor    switch    treatment    lipopharma    preclinical    identifier    statistically    underlying    lipid    activator    written    therapeutic    ema    anticancer    medicines    protein    glioma    highest    conditional    sa    clinicaltrials    designated    approximately    perform    scientific    2014    context    biomarkers    efficacious    trial    disease    clinical    iib    membrane    demonstrated    lack    transducers    cell    discovery    agency    innovative    man    demonstrates    iia    marketing    recruitment    obtain    formal    molar    sme    proliferation    report    advice    pa    sphingomyelin    plausible    indicates    humans    orphan    pe    protocol    diagnosis    months    designed    safety    patients    first    brain    positive    chmp    personalized    showed    glioblastoma    molecular    efficacy    nct01792310    action    prevalence    form    alternatives    sawp773534    gt    basis    glp    multiforme    half    gov    mortality    authorisation    sm    inhabitants    submitted    assistance    synthase    2ohoa    rare    prognosis    mechanism    sms1    aggressive   

Project "CLINGLIO" data sheet

The following table provides information about the project.

Coordinator
LAMINAR PHARMACEUTICALS SL 

Organization address
address: CTRA VALLDEMOSSA KM 7,4 PARCBIT, EDIFICIO 17, INCU EMPRESAS, 2A PLANTA, MODULO C - 8
city: PALMA DE MALLORCA
postcode: 7121
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://clinglio.eu/
 Total cost 6˙155˙125 €
 EC max contribution 6˙155˙125 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LAMINAR PHARMACEUTICALS SL ES (PALMA DE MALLORCA) coordinator 2˙582˙500.00
2    SPECIALIZED MEDICAL SERVICES-ONCOLOGY BV NL (SCHIPHOL) participant 1˙212˙500.00
3    PRAXIS PHARMACEUTICAL SA ES (MINANO MAYOR) participant 1˙103˙500.00
4    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 238˙750.00
5    RESEARCH FUND OF THE HADASSAH MEDICAL ORGANIZATION (R.A) IL (JERUSALEM) participant 222˙500.00
6    UNIVERSITAT DE LES ILLES BALEARS ES (PALMA DE MALLORCA) participant 195˙500.00
7    FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA IT (MILANO) participant 117˙000.00
8    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) participant 117˙000.00
9    THE ROYAL MARSDEN NATIONAL HEALTH SERVICE TRUST UK (London) participant 117˙000.00
10    UNIVERSITA DEGLI STUDI DI SALERNO IT (FISCIANO SA) participant 101˙875.00
11    LIPODOM KUTATO FEJLESZTO ES TANACSADO KORLATOLT FELELOSSEGU TARSASAG HU (SZEGED) participant 97˙000.00
12    LANA MANAGEMENT AND BUSINESS RESEARCH INTERNATIONAL LLC US (ACTON, MASSACHUSETTS) participant 50˙000.00

Map

 Project objective

'Glioma is a rare brain cancer with one of the highest mortality rates. It is considered an orphan disease due to its low prevalence (less than 0.5 cases per 10,000 inhabitants in the EU) and the lack of plausible therapies. Based on the discovery of the lipid proliferation switch (high membrane PE-to-SM molar ratio that enables recruitment of cell growth transducers to the membrane), the SME Lipopharma (leading this application) defined a novel anticancer drug target, the tumor repressor protein sphingomyelin synthase 1 (SMS1). An innovative SMS1 activator, 2OHOA, was designed and showed safety and efficacy in preclinical GLP and non-GLP studies. A first-in-man clinical trial I/IIa (ClinicalTrials.gov identifier #NCT01792310) further demonstrated its safety and efficacy in humans. The European Medicines Agency (EMA) designated 2OHOA orphan drug for the treatment of glioma and approximately half of the patients with glioma submitted to >2 months of treatment showed positive response. The present project aims to perform a clinical phase IIB study to demonstrate 2OHOA’s efficacy against glioblastoma multiforme, the most aggressive form of glioma. In this context, a written formal report from the EMA after scientific advice and protocol assistance (SA/PA-EMA/CHMP/SAWP773534/2014) indicates that 2OHOA would obtain Conditional Marketing Authorisation if this phase-IIB study further demonstrates statistically significant efficacy. In addition this project will further investigate 2OHOA’s safety, mechanism of action and biomarkers for glioblastoma diagnosis, prognosis and response to 2OHOA treatment. These studies will let us (i) know the molecular basis underlying the response to 2OHOA treatment, (ii) define new biomarkers, (iii) design more efficacious personalized treatments and (iv) investigate therapeutic alternatives in patients who do not respond to treatment.'

 Deliverables

List of deliverables.
Protocols and laboratory manual for miRNAS, mRNA expression and RNAseq Documents, reports 2020-01-30 10:06:15
Consititution of the different management bodies Documents, reports 2020-01-30 10:06:15
Clinical Trial registration number Demonstrators, pilots, prototypes 2020-01-30 10:06:15
Sample protocols for liquid biopsy biomarkers Documents, reports 2020-01-30 10:06:15
Public Web Site and Project Presentation Other 2020-01-30 10:06:15
First regulatory approval of final version of study protocol Websites, patent fillings, videos etc. 2020-01-30 10:06:15
Protocols for protein biomarker determinations Documents, reports 2020-01-30 10:06:15

Take a look to the deliverables list in detail:  detailed list of CLINGLIO deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Wessal Massalha, Mark Markovits, Edward Pichinuk, Yael Feinstein-Rotkopf, Mark Tarshish, Kumudesh Mishra, Victoria Llado, Miguel Weil, Pablo V. Escriba, Or Kakhlon
Minerval (2-hydroxyoleic acid) causes cancer cell selective toxicity by uncoupling oxidative phosphorylation and compromising bioenergetic compensation capacity
published pages: BSR20181661, ISSN: 0144-8463, DOI: 10.1042/bsr20181661
Bioscience Reports 39/1 2020-01-30
2019 Francisca Guardiola-Serrano, Roberto Beteta-Göbel, Raquel Rodríguez-Lorca, Maitane Ibarguren, David J. López, Silvia Terés, María Alonso-Sande, Mónica Higuera, Manuel Torres, Xavier Busquets, Pablo V. Escribá
The triacylglycerol, hydroxytriolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.26824
Oncotarget 10/26 2020-01-30
2019 Doralicia Casares, Pablo V. Escribá, Catalina Ana Rosselló
Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues
published pages: 2167, ISSN: 1422-0067, DOI: 10.3390/ijms20092167
International Journal of Molecular Sciences 20/9 2020-01-30
2019 Paula Fernández-García, Catalina A. Rosselló, Raquel Rodríguez-Lorca, Roberto Beteta-Göbel, Javier Fernández-Díaz, Victoria Lladó, Xavier Busquets, Pablo V. Escribá
The Opposing Contribution of SMS1 and SMS2 to Glioma Progression and Their Value in the Therapeutic Response to 2OHOA
published pages: 88, ISSN: 2072-6694, DOI: 10.3390/cancers11010088
Cancers 11/1 2020-01-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CLINGLIO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CLINGLIO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More